AstraZeneca Pharma India has announced plans to sell its 64-acre production facility in North Bengaluru. This decision aligns with a broader strategic review of the company’s global manufacturing and supply network, undertaken by its UK-based parent company, AstraZeneca.
The review aims to optimize the company’s global production footprint by streamlining operations and reallocating resources to enhance efficiency and innovation. The North Bengaluru facility, which has been a key part of AstraZeneca India’s manufacturing ecosystem, is now being evaluated for sale as part of this restructuring effort.
While the pharmaceutical giant remains committed to India, this move signals a shift in its operational strategy, focusing on agile and cost-effective supply chain management. Industry experts believe the sale could attract significant interest from domestic and international pharmaceutical players, given the facility’s prime location and infrastructure.
AstraZeneca India has yet to disclose further details about the timeline and potential buyers for the facility. However, this step is expected to align with the company’s long-term vision of reinforcing its global production network while ensuring continued access to high-quality medicines in India and beyond.
Discussion about this post